← Leaderboards
Li Lily Wang
Dartmouth College
$7,371,035
Attributed
$10,569,290
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,569,290 · 7
By mechanism
R01$9,745,864 · 5
R21$823,426 · 2
Top collaborators
- Ming You5 shared
- Efstathios Karathanasis4 shared
- Zheng-Rong Lu1 shared
- Jaroslaw P Maciejewski1 shared
Others in their field
Top investigators on “T-Cell Activation”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$39,889,328
- Joseph B. Margolick · Johns Hopkins University$33,728,823
- Arlene H Sharpe · Harvard Medical School$29,805,380
- Paul Glyndwr Thomas · Boston Children'S Hospital$27,737,491
- Eric Hunter · University Of Alabama At Birmingham$27,460,045
- Douglas F Nixon · J. David Gladstone Institutes$26,513,229
Research focus
T-Cell ActivationProteinsTumor ImmunityTumorT-LymphocyteMediatingCancer ImmunotherapyImmunoglobulin DomainSuppressor-Effector T-LymphocytesImmune CheckpointT Cell ResponseMalignant NeoplasmsImmuneMonoclonal AntibodiesSignal TransductionCheckpoint ReceptorsDesignResponseBindingMyeloid CellsReceptorMutantLigandsPathway Interactions
Grant awards (25)
Investigating the Role of VISTA in Driving Immune Evasion in Acute Myeloid Leukemia$654,837
R01 · FY2025 · CA · contact PI
Anticancer ELNP nanovaccines for curative treatmentof pancreatic cancer$654,681
R01 · FY2025 · CA
Dual action immunostimulatory nanoparticles for treatment of aggressive cancers$540,823
R01 · FY2025 · CA
Dual action immunostimulatory nanoparticles for treatment of aggressive cancers$570,868
R01 · FY2024 · CA
Investigating a Novel Inhibitory Receptor in Regulating CAR-T Cell Persistence and Function$413,971
R21 · FY2024 · CA · contact PI
Dual action immunostimulatory nanoparticles for treatment of aggressive cancers$77,121
R01 · FY2024 · CA
Dual action immunostimulatory nanoparticles for treatment of aggressive cancers$600,913
R01 · FY2023 · CA
Vista, A Novel Checkpoint that Suppresses Anti-Tumor T Cell Responses$340,606
R01 · FY2023 · CA · contact PI
The Roles of a Novel Immune-Checkpoint Receptor Complex in Driving T Cell Dysfunction in Cancer$221,286
R21 · FY2023 · CA · contact PI
Transfer Application - R01 CA223804 - Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer$668,650
R01 · FY2022 · CA
Vista, A Novel Checkpoint that Suppresses Anti-Tumor T Cell Responses$340,606
R01 · FY2022 · CA · contact PI
The Roles of a Novel Immune-Checkpoint Receptor Complex in Driving T Cell Dysfunction in Cancer$188,169
R21 · FY2022 · CA · contact PI
Transfer Application - R01 CA223804 - Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer$713,044
R01 · FY2021 · CA
Vista, A Novel Checkpoint that Suppresses Anti-Tumor T Cell Responses$347,558
R01 · FY2021 · CA · contact PI
Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer$640,450
R01 · FY2020 · CA
Vista, A Novel Checkpoint that Suppresses Anti-Tumor T Cell Responses$347,558
R01 · FY2020 · CA · contact PI
Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer$621,239
R01 · FY2019 · CA
Vista, A Novel Checkpoint that Suppresses Anti-Tumor T Cell Responses$358,678
R01 · FY2019 · CA · contact PI
Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer$653,885
R01 · FY2018 · CA
VISTA, a novel checkpoint that suppresses anti-tumor T cell responses$301,885
R01 · FY2017 · CA · contact PI
VISTA, a novel checkpoint that suppresses anti-tumor T cell responses$15,589
R01 · FY2016 · CA · contact PI
VISTA, a novel checkpoint that suppresses anti-tumor T cell responses$338,521
R01 · FY2015 · CA · contact PI
VISTA, a novel checkpoint that suppresses anti-tumor T cell responses$307,951
R01 · FY2014 · CA · contact PI
VISTA, a novel checkpoint that suppresses anti-tumor T cell responses$315,981
R01 · FY2013 · CA · contact PI
VISTA, a novel checkpoint that suppresses anti-tumor T cell responses$334,420
R01 · FY2012 · CA · contact PI